Abstract
Chemokines are members of the superfamily of cytokines involved in: (i) cell migration to sites of infection; or (ii) cellular stress during an immune response. Human CXCL14/BRAK is a monocyte-selective chemokine expressed in all normal tissues, but is also involved in the development of several cancers. We describe the expression, structural characterization and biological activity of an N-terminal truncated mutant of CXCL14, ΔCXCL14, where the first eleven residues and the two disulphide bridges were removed. We designed this species in order to analyse the biological importance of the disulphide bonds and the flexible N terminus of CXCL14 for its protein folding, stability and function. The mutant ΔCXCL14 is biologically active, as suggested by the in vitro assays with migration of pancreatic cancer cells, but also its structure is not well-fixed, as suggested by fluorescence, CD and NMR. We conclude that the disulphide bridges are important in maintaining the structure of this chemokine, but they are not necessary for the biological activity of CXCL14 species.
Keywords: Binding, circular dichroism, fluorescence, folding, NMR, structure, stability.
Protein & Peptide Letters
Title:An N-terminally Truncated Mutant of Human Chemokine CXCL14 has Biological Activity
Volume: 20 Issue: 8
Author(s): Jose L. Neira, María J. Sandí, Julio Bacarizo, Cendrine Archange, Ana Camara- Artigas and Juan L. Iovanna
Affiliation:
Keywords: Binding, circular dichroism, fluorescence, folding, NMR, structure, stability.
Abstract: Chemokines are members of the superfamily of cytokines involved in: (i) cell migration to sites of infection; or (ii) cellular stress during an immune response. Human CXCL14/BRAK is a monocyte-selective chemokine expressed in all normal tissues, but is also involved in the development of several cancers. We describe the expression, structural characterization and biological activity of an N-terminal truncated mutant of CXCL14, ΔCXCL14, where the first eleven residues and the two disulphide bridges were removed. We designed this species in order to analyse the biological importance of the disulphide bonds and the flexible N terminus of CXCL14 for its protein folding, stability and function. The mutant ΔCXCL14 is biologically active, as suggested by the in vitro assays with migration of pancreatic cancer cells, but also its structure is not well-fixed, as suggested by fluorescence, CD and NMR. We conclude that the disulphide bridges are important in maintaining the structure of this chemokine, but they are not necessary for the biological activity of CXCL14 species.
Export Options
About this article
Cite this article as:
Neira L. Jose, Sandí J. María, Bacarizo Julio, Archange Cendrine, Artigas Camara- Ana and Iovanna L. Juan, An N-terminally Truncated Mutant of Human Chemokine CXCL14 has Biological Activity, Protein & Peptide Letters 2013; 20 (8) . https://dx.doi.org/10.2174/09298665113209990040
DOI https://dx.doi.org/10.2174/09298665113209990040 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Alzheimers Disease, Ceramide, Visfatin and NAD
CNS & Neurological Disorders - Drug Targets New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)
Current Pharmaceutical Design Regulation of Dendritic Cell Function Through Toll-Like Receptors
Current Molecular Medicine Editorial [Hot topic: General Aspects of Biologic Agents in Rheumatology (Guest Editor: Omer Faruk Sendur)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pharmacological Treatments for Neovascular Age-Related Macular Degeneration: Can Mixed Treatment Comparison Meta-Analysis be Useful?
Current Drug Targets Augmenting the Xanthine Oxidase Inhibitory Activity of Febuxostat by its Structural Modification
Letters in Drug Design & Discovery Role of MicroRNA in the Diagnosis and Therapy of Hepatocellular Carcinoma: A New Frontier
MicroRNA Recent Advances in the Comprehension and the Management of Perioperative Systemic Host Response During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery Silencing of Tumor Necrosis Factor Receptor-1 in Human Lung Microvascular Endothelial Cells Using Particle Platforms for siRNA Delivery
Current Drug Targets Whole Milk and Full-Fat Dairy Products and Hypertensive Risks
Current Hypertension Reviews Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry Cyclooxygenase and Atherosclerosis: A Smoking Area
Current Pharmaceutical Design The Role of Procalcitonin in Sepsis and Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Inhibitors of the Metalloproteinase Anthrax Lethal Factor
Current Topics in Medicinal Chemistry Pathway to the Clinic: Inhibition of P38 MAP Kinase. A Review of Ten Chemotypes Selected for Development
Current Topics in Medicinal Chemistry Is Autoimmunity a Component of Natural Immunity to HIV?
Current HIV Research The State-of-Art in Angiogenic Properties of Latex from Different Plant Species
Current Angiogenesis (Discontinued) Chemogenomics Approaches for Receptor Deorphanization and Extensions of the Chemogenomics Concept to Phenotypic Space
Current Topics in Medicinal Chemistry Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets